Cerebrolysin
A porcine brain-derived neuropeptide complex that mimics endogenous neurotrophic factors to support neuronal survival, plasticity, and recovery after brain injury.
Cerebrolysin is a standardized, low-molecular-weight preparation of neuropeptides and free amino acids extracted from purified porcine brain proteins, developed by EVER Neuro Pharma (Austria). It crosses the blood-brain barrier and acts as a BDNF/NGF-mimetic, promoting neuronal survival, synaptic plasticity, and neurogenesis in damaged or degenerating tissue. Approved and widely used in Russia, Eastern Europe, China, and other countries for stroke, traumatic brain injury, vascular dementia, and Alzheimer's disease, it remains investigational and not FDA-approved in the United States. Its evidence base is substantial but heterogeneous, drawn largely from Eastern European clinical trials of variable quality.
Class
Porcine brain-derived neuropeptide complex (neurotrophic preparation)
Half-life
~2-4 hours (varies by component)
Routes
Intravenous (IV infusion), Intramuscular (IM)
Category
Cognitive & Nootropic
Researched benefits
What it's studied for
Neuroprotection after acute injury
Reduces neuronal death in models of ischemia, hypoxia, and excitotoxicity via anti-apoptotic and anti-inflammatory actions. A 6-month prospective cohort in moderate traumatic brain injury found greater functional recovery and improved survival when added to standard care.
Stroke and cognitive recovery
Cerebrolysin's strongest evidence base is post-stroke rehabilitation, where multiple controlled trials have evaluated cognitive and functional recovery. Cochrane meta-analyses cover acute ischemic stroke with mostly positive but heterogeneous outcomes.
Vascular dementia support
A Cochrane systematic review of 6 RCTs (597 participants) found intravenous Cerebrolysin improved cognition and global function in vascular dementia versus placebo without increased adverse effects, though evidence quality was rated very low.
Slowing cognitive decline / dementia prevention
A 3-year prospective comparative study reported that annual IV courses reduced the rate of cognitive deficit progression and conversion from amnestic mild cognitive impairment to dementia in elderly patients, suggesting a possible disease-modifying effect.
Synaptic plasticity and memory
Increases long-term potentiation in hippocampal slices and modulates cholinergic (acetylcholine) pathways relevant to learning and memory, mechanisms proposed to underlie memory improvement and cognitive optimization.
Neurogenesis and repair
Supports proliferation of neural stem cells in the subventricular zone in rodent models and mimics endogenous neurotrophic factors (BDNF, NGF, CNTF) to aid regeneration in injured brain tissue.
Mechanism
How it works
Cerebrolysin is a standardized mixture of low-molecular-weight neuropeptides and free amino acids derived from purified porcine cortical proteins. Its components are small enough to cross the blood-brain barrier, where they are proposed to mimic the actions of endogenous neurotrophic factors such as brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF). Rather than acting on a single molecular target, it exerts a multi-pathway, growth-factor-like influence on neuronal survival and metabolism.
At the cellular level the preparation is anti-apoptotic, reducing neuronal death in models of ischemia, hypoxia, and excitotoxicity, and anti-inflammatory, suppressing microglial activation after injury. These protective effects underlie its use in acute settings such as stroke and traumatic brain injury.
Cerebrolysin also promotes synaptic plasticity, increasing long-term potentiation in hippocampal slices, and supports neurogenesis by increasing proliferation of neural stem cells in the subventricular zone in rodent models. It additionally modulates cholinergic pathways relevant to learning and memory, contributing to its cognitive-recovery profile.
Emerging preclinical work suggests further mechanisms: exosomes released by Cerebrolysin-treated cerebral endothelial cells can restore blood-brain-barrier integrity impaired by fibrin or tPA, and the compound can reduce kynurenic acid formation, reversing learning impairment in a simple invertebrate memory model. Together these findings frame Cerebrolysin as a broad neurotrophic and neuroprotective agent rather than a targeted single-receptor drug.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Cerebrolysin is supplied as a ready-to-use sterile ampoule/vial solution and is not reconstituted from lyophilized powder like most research peptides. For IV administration it is typically diluted (slow infusion) in saline; IM doses are given directly.
Beginner
- Dose
- 5 ml/day (~215 mg active peptide concentration)
- Frequency
- Once daily
- Timing
- Morning (AM)
- Duration
- 10-day cycles
- Route
- Intramuscular (IM)
First-time use, general cognitive enhancement research, and mild cognitive complaints.
Intermediate
- Dose
- 10 ml/day
- Frequency
- Once daily
- Timing
- Consistent daily time
- Duration
- 14-21 day cycles, repeated every 2-3 months
- Route
- Intramuscular (IM)
Post-concussion recovery research and cognitive optimization protocols.
Advanced
- Dose
- 20-30 ml/day (slow infusion in saline)
- Frequency
- Once daily
- Timing
- Clinical schedule
- Duration
- 10-21 day cycles
- Route
- Intravenous (IV, clinical setting only)
Acute neurological event recovery (clinical only) and Alzheimer's research protocols; higher IV doses should only be administered under medical supervision.
- Overall summary range: 5-30 ml/day, once daily, IM or IV, in 10-30 day cycles repeated every 2-3 months.
- In approved markets the standard clinical/research protocol is a course of 10-20 IV infusion sessions.
- IV administration should be a slow infusion diluted in saline and performed in a clinical setting only.
- Higher doses (20-30 ml) are reserved for acute neurological recovery and dementia research under supervision.
Evidence
Research & clinical studies (5)
Cerebrolysin for vascular dementia
Across 6 RCTs (597 participants), intravenous Cerebrolysin improved cognition and global function in vascular dementia versus placebo with no increase in adverse effects, though all evidence was very low quality due to high risk of bias and heterogeneity.
PMID 31710397Cerebrolysin in the preventive therapy of dementia in elderly patients with mild cognitive impairment: a three-year prospective comparative study
Annual IV courses of Cerebrolysin reduced the rate of cognitive deficit progression and conversion from amnestic mild cognitive impairment to dementia versus untreated controls (n=100), suggesting a disease-modifying effect.
PMID 39435777Neuroprotective Effects of Cerebrolysin in Moderate Traumatic Brain Injury with Nonoperative Lesions: A 6-Month Prospective Cohort Analysis
Adults with moderate TBI and nonoperative intracerebral hemorrhage who received Cerebrolysin plus standard care showed significantly greater functional and cognitive recovery, higher independence scores, and improved 6-month survival with no increase in adverse events.
PMID 42110924Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothelial Cell Permeability
Exosomes from Cerebrolysin-treated cerebral endothelial cells restored integrity of endothelial cells damaged by fibrin or tPA, reducing inflammation/coagulation proteins while increasing tight-junction and metabolic proteins.
PMID 42193943Biochemical and Pharmacological Studies on Kynurenic Acid Metabolism in the Helix pomatia Snail Model of Learning and Memory
Cerebrolysin decreased kynurenic acid formation in snail tissue and reversed learning impairment caused by elevated kynurenic acid, suggesting a mechanism supporting cognitive function.
PMID 42072724Combinations
Stacking & blends
Neurotrophic recovery pairing
Broad neurotrophic support for post-stroke or encephalopathy recovery research
Both are brain-derived low-molecular-weight peptide preparations positioned as broad-spectrum neurotrophic agents that mimic endogenous neurotrophic factors, used in overlapping Eastern European clinical contexts.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Epilepsy / status epilepticus
- Renal failure or severe renal impairment
- Porcine protein or known peptide allergy
- Pregnancy and lactation
Cerebrolysin has a moderate risk profile in research contexts and is generally well tolerated in trials, with no consistent increase in adverse events reported. Because it is derived from porcine brain protein, individuals with pork/protein allergies should avoid it, and it is contraindicated in seizure disorders and significant renal impairment. Review all contraindications and administer under qualified supervision, particularly for IV protocols.
FAQ
Cerebrolysin — common questions
What is Cerebrolysin?
Cerebrolysin is a brain-derived polypeptide preparation made from purified porcine cortical proteins, composed of low-molecular-weight neuropeptides and free amino acids that cross the blood-brain barrier. It mimics endogenous neurotrophic factors to support neuronal survival, synaptic plasticity, and metabolic activity in damaged or degenerating brain tissue.
What is Cerebrolysin primarily studied for?
Its main research areas are neuroprotection, neuroplasticity, memory improvement, and cognitive recovery — clinically explored in stroke rehabilitation, traumatic brain injury, vascular dementia, and Alzheimer's disease.
How is Cerebrolysin administered and dosed?
It is given by intramuscular injection or intravenous infusion, once daily, typically 5-30 ml/day in 10-30 day cycles repeated every 2-3 months. Beginner research protocols use ~5 ml/day IM, while advanced/clinical protocols use 20-30 ml/day by slow IV infusion in a clinical setting.
Is Cerebrolysin FDA-approved?
No. It is investigational and research-only in the United States, with Phase 2/3 trials under an active IND but no NDA filed. It is an approved prescription neuroprotective medication in Russia, Eastern Europe, China, South Korea, Mexico, and 50+ other countries.
How strong is the evidence for Cerebrolysin?
The published literature is substantial but heterogeneous. A Cochrane review of 6 RCTs found cognitive and functional improvement in vascular dementia, and cohort and prospective studies support benefit in TBI and mild cognitive impairment, but much of the evidence is rated low quality due to bias and variable trial methodology.
What are the side effects and contraindications?
Cerebrolysin is generally well tolerated; the most common effect is a mild injection site reaction. It is contraindicated in epilepsy/status epilepticus, renal failure, porcine protein or peptide allergy, and pregnancy/lactation.
